Profund Advisors LLC Increases Stock Holdings in Twist Bioscience Corporation $TWST

Profund Advisors LLC lifted its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 71.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,355 shares of the company’s stock after buying an additional 17,701 shares during the quarter. Profund Advisors LLC owned approximately 0.07% of Twist Bioscience worth $1,344,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its holdings in Twist Bioscience by 11.2% during the 4th quarter. ProShare Advisors LLC now owns 13,636 shares of the company’s stock valued at $433,000 after acquiring an additional 1,375 shares in the last quarter. Maxi Investments CY Ltd purchased a new position in shares of Twist Bioscience during the 4th quarter worth approximately $1,110,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Twist Bioscience by 11.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,668 shares of the company’s stock worth $1,447,000 after purchasing an additional 4,704 shares in the last quarter. SBI Securities Co. Ltd. raised its position in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares during the last quarter. Finally, Benjamin Edwards Inc. lifted its stake in Twist Bioscience by 4.6% in the 4th quarter. Benjamin Edwards Inc. now owns 29,632 shares of the company’s stock valued at $940,000 after buying an additional 1,309 shares in the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on TWST. Evercore raised their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Guggenheim increased their price objective on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Barclays lifted their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Finally, Robert W. Baird upped their target price on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $56.57.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $60.00, for a total value of $240,000.00. Following the completion of the sale, the chief financial officer directly owned 118,694 shares in the company, valued at approximately $7,121,640. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total transaction of $673,440.00. Following the transaction, the director directly owned 17,754 shares of the company’s stock, valued at $996,354.48. This trade represents a 40.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 46,551 shares of company stock worth $2,566,533. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Price Performance

TWST stock opened at $53.66 on Thursday. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $66.06. The stock’s fifty day simple moving average is $52.03 and its 200-day simple moving average is $42.95. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $3.34 billion, a price-to-earnings ratio of -40.35 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. During the same quarter in the previous year, the company posted ($0.66) earnings per share. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. Equities research analysts expect that Twist Bioscience Corporation will post -1.86 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.